Simply Wall St.

Verici Dx First Half 2024 Earnings: US$0.006 loss per share (vs US$0.031 loss in 1H 2023)

editorial-team@simplywallst.com (Simply Wall St)
1 min read

In This Article:

Verici Dx (LON:VRCI) First Half 2024 Results

Key Financial Results

  • Revenue: US$3.34m (up by US$3.32m from 1H 2023).

  • Net loss: US$1.35m (loss narrowed by 74% from 1H 2023).

  • US$0.006 loss per share (improved from US$0.031 loss in 1H 2023).

earnings-and-revenue-history
AIM:VRCI Earnings and Revenue History July 21st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Verici Dx Earnings Insights

Looking ahead, revenue is forecast to grow 69% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in the United Kingdom.

Performance of the British Biotechs industry.

The company's shares are up 15% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 4 warning signs for Verici Dx you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

and

Recommended Stories